Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAGGED: Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
NCT04535271Phase 2Recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- Sep 2021
- Primary completion
- Sep 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin in leiomyosarcoma (LMS), sponsored by Cancer Institute Medical Group. Started Sep 2021; status: recruiting.
02
Drugs
trabectedin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04535271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535271.